Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
2003 1
2005 2
2006 1
2008 1
2009 3
2010 2
2011 5
2012 4
2013 2
2014 3
2015 1
2016 1
2017 1
2018 1
2019 1
2020 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic activity of Sindbis virus in human oral squamous carcinoma cells.
Saito K, Uzawa K, Kasamatsu A, Shinozuka K, Sakuma K, Yamatoji M, Shiiba M, Shino Y, Shirasawa H, Tanzawa H. Saito K, et al. Br J Cancer. 2009 Aug 18;101(4):684-90. doi: 10.1038/sj.bjc.6605209. Epub 2009 Jul 28. Br J Cancer. 2009. PMID: 19638980 Free PMC article.
BACKGROUND: Sindbis virus (SIN) infection causes no or only mild symptoms (fever, rash, and arthralgia) in humans. However, SIN has a strong cytopathic effect (CPE) on various cancer cells. This study focuses on the oncolytic activity of SIN AR399 on oral can …
BACKGROUND: Sindbis virus (SIN) infection causes no or only mild symptoms (fever, rash, and arthralgia) in humans. However, SI …
Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors.
Scherwitzl I, Opp S, Hurtado AM, Pampeno C, Loomis C, Kannan K, Yu M, Meruelo D. Scherwitzl I, et al. Mol Ther Oncolytics. 2020 May 6;17:431-447. doi: 10.1016/j.omto.2020.04.012. eCollection 2020 Jun 26. Mol Ther Oncolytics. 2020. PMID: 32478167 Free PMC article.
We have developed a practical and improved strategy for cancer immunotherapy using an oncolytic virus and anti-OX40. This strategy takes advantage of a preexisting T cell immune repertoire in vivo, removing the need to know about present tumor antigens. We have show …
We have developed a practical and improved strategy for cancer immunotherapy using an oncolytic virus and anti-OX40. This stra …
Tissue-specific attenuation of oncolytic sindbis virus without compromised genetic stability.
Kueberuwa G, Cawood R, Tedcastle A, Seymour LW. Kueberuwa G, et al. Hum Gene Ther Methods. 2014 Apr;25(2):154-65. doi: 10.1089/hgtb.2013.202. Hum Gene Ther Methods. 2014. PMID: 24568203
Wild-type Sindbis virus (SV) shows promise as an oncolytic agent, although potential off-target replication is a safety concern. To remove possible pathology reflecting virus replication in liver, muscle, and/or hematopoietic cells, microRNA (miR)-resp …
Wild-type Sindbis virus (SV) shows promise as an oncolytic agent, although potential off-target replication is a safety …
Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.
Huang PY, Guo JH, Hwang LH. Huang PY, et al. Mol Ther. 2012 Feb;20(2):298-305. doi: 10.1038/mt.2011.245. Epub 2011 Nov 8. Mol Ther. 2012. PMID: 22068428 Free PMC article.
Sindbis virus (SBV) has been shown to possess oncolytic potential in many human xenograft tumor models in immunocompromised mice. ...
Sindbis virus (SBV) has been shown to possess oncolytic potential in many human xenograft tumor models in immunocomprom
Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain.
Takenouchi A, Saito K, Saito E, Saito T, Hishiki T, Matsunaga T, Isegawa N, Yoshida H, Ohnuma N, Shirasawa H. Takenouchi A, et al. Pediatr Surg Int. 2015 Dec;31(12):1151-9. doi: 10.1007/s00383-015-3784-y. Epub 2015 Aug 23. Pediatr Surg Int. 2015. PMID: 26298056
PURPOSE: With current treatment regimens, high-risk neuroblastoma (NB) remains largely incurable. Oncolytic viral therapy uses replication-competent viruses, like Sindbis virus (SINV), to kill cancers. ...CONCLUSION: Our results suggested that SINV AR339 was …
PURPOSE: With current treatment regimens, high-risk neuroblastoma (NB) remains largely incurable. Oncolytic viral therapy uses replic …
Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH. Thorne SH. Curr Opin Mol Ther. 2008 Aug;10(4):387-92. Curr Opin Mol Ther. 2008. PMID: 18683104
Less research has been directed at making incremental improvements in original vectors based mainly on strains of adenovirus and HSV; instead a variety of different viral strains have been suggested as potential backbones for future oncolytic viruses (including Newcastle d …
Less research has been directed at making incremental improvements in original vectors based mainly on strains of adenovirus and HSV; instea …
Oncolytic Alphaviruses in Cancer Immunotherapy.
Lundstrom K. Lundstrom K. Vaccines (Basel). 2017 Apr 12;5(2):9. doi: 10.3390/vaccines5020009. Vaccines (Basel). 2017. PMID: 28417936 Free PMC article. Review.
In parallel to oncolytic viral vectors based on adenoviruses and herpes simplex viruses, oncolytic RNA viruses and particularly alphaviruses have been evaluated as delivery vehicles. Immunization studies in experimental rodent models for various cancers including gl …
In parallel to oncolytic viral vectors based on adenoviruses and herpes simplex viruses, oncolytic RNA viruses and particularl …
Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity.
Scherwitzl I, Hurtado A, Pierce CM, Vogt S, Pampeno C, Meruelo D. Scherwitzl I, et al. Mol Ther Oncolytics. 2018 May 3;9:51-63. doi: 10.1016/j.omto.2018.04.004. eCollection 2018 Jun 29. Mol Ther Oncolytics. 2018. PMID: 29988525 Free PMC article.
Oncolytic viruses represent a promising form of cancer immunotherapy. We investigated the potential of Sindbis virus (SV) for the treatment of solid tumors expressing the human cancer testis antigen NYESO-1. ...
Oncolytic viruses represent a promising form of cancer immunotherapy. We investigated the potential of Sindbis virus (S
Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain.
Unno Y, Shino Y, Kondo F, Igarashi N, Wang G, Shimura R, Yamaguchi T, Asano T, Saisho H, Sekiya S, Shirasawa H. Unno Y, et al. Clin Cancer Res. 2005 Jun 15;11(12):4553-60. doi: 10.1158/1078-0432.CCR-04-2610. Clin Cancer Res. 2005. PMID: 15958641 Free article.
PURPOSE: Recently, the application of replication-competent viruses has been studied as anticancer agents. Sindbis virus (SIN) is an RNA virus that belongs to the Alphavirus genus in the Togaviridae virus family. ...RESULTS: SIN infection was able to i …
PURPOSE: Recently, the application of replication-competent viruses has been studied as anticancer agents. Sindbis virus (SIN) …
Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells.
Mohankumar V, Dhanushkodi NR, Raju R. Mohankumar V, et al. Biochem Biophys Res Commun. 2011 Mar 11;406(2):262-7. doi: 10.1016/j.bbrc.2011.02.030. Epub 2011 Feb 18. Biochem Biophys Res Commun. 2011. PMID: 21316343 Free PMC article.
Genetically engineered Sindbis viruses (SIN) are excellent oncolytic agents in preclinical models. Several human cancers have aberrant Akt signaling, and kinase inhibitors including rapamycin are currently tested in combination therapies with oncolytic viruse …
Genetically engineered Sindbis viruses (SIN) are excellent oncolytic agents in preclinical models. Several human cancers have …
29 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback